This is very very important and may explain the similar attack rates in the seropositives and seronegatives in the placebo arm of the Novavax trial in South Africa! https://t.co/IzvVhtBVbM— Florian Krammer (@florian_krammer) March 10, 2021
This is very very important and may explain the similar attack rates in the seropositives and seronegatives in the placebo arm of the Novavax trial in South Africa! https://t.co/IzvVhtBVbM